April 13 (Reuters) - Cybin Inc CYBN.NLB :* CYBIN ADVANCES IND-ENABLING STUDIES OF TWO PSYCHEDELIC MOLECULES, CYB003 AND CYB004 FOR INVESTIGATIONAL NEW DRUG APPLICATIONS
March 3 (Reuters) - Cybin Inc CYBN.NLB :* CYBIN INC. ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET
Jan 18 (Reuters) - Cybin Inc CYBN.NLB :* CYBIN ANNOUNCES CDN$20 MILLION BOUGHT DEAL OFFERING* CYBIN-ENTERED INTO AGREEMENT WITH CANACCORD GENUITY ON BEHALF OF A SYNDICATE OF...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Strong Sell | Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 0.00 | 0.00 | +0.06 | +68.75% | 1.77M | TSXV | |||
| 0.015 | 0.00 | 0.00 | -0.005 | -25.00% | 15.10K | CSE | |||
| 2.09 | 2.18 | 2.07 | -0.0600 | -2.79% | 3.70M | Toronto | |||
| 2.04 | 2.065 | 2.01 | -0.010 | -0.49% | 4.02M | Toronto | |||
| 3.80 | 3.86 | 3.78 | -0.020 | -0.52% | 5.93M | Toronto | |||
| 132.64 | 132.92 | 132.16 | -0.04 | -0.03% | 1.68M | Toronto | |||
| 0.075 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | TSXV | |||
| 39.07 | 39.31 | 37.76 | +0.95 | +2.49% | 96.94K | Toronto | |||
| 3.20 | 3.35 | 3.01 | -0.2400 | -6.98% | 123.23K | Toronto | |||
| 67.28 | 67.68 | 66.92 | -0.42 | -0.62% | 150.19K | Toronto | |||
| 1.72 | 2.08 | 1.62 | +0.130 | +8.18% | 301.05K | TSXV | |||
| 107.76 | 108.38 | 107.11 | -0.14 | -0.13% | 64.28K | Toronto | |||
| 72.52 | 72.56 | 71.89 | -0.18 | -0.25% | 864.82K | Toronto | |||
| 1.13 | 1.17 | 1.08 | +0.05 | +4.63% | 5.93M | Toronto | |||
| 3.46 | 3.54 | 3.36 | +0.07 | +2.06% | 1.43M | Toronto |
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.